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Background: AMPK phosphorylates CFTR and inhibits PKA-stimulated CFTR channel gating by unclear mechanisms.
Results: NDPK-A, AMPK, and CFTR exist in a membrane-associated complex. AMPK-CFTR binding and NDPK-A catalytic
function are required for CFTR inhibition by AMPK.
Conclusion: NDPK-A plays an integral role in the regulation of CFTR by AMPK.
Significance: Targeting the AMPK-CFTR interaction and NDPK-A function could yield new therapeutic strategies for CF.
Cystic fibrosis transmembrane conductance regulator
(CFTR) Cl channel mutations cause cystic fibrosis lung dis-
ease. A better understanding of CFTR regulatory mechanisms
could suggest new therapeutic strategies. AMP-activated pro-
tein kinase (AMPK) binds to and phosphorylates CFTR, attenu-
ating PKA-activated CFTR gating. However, the requirement
for AMPK binding to CFTR and the potential role of other pro-
teins in this regulation are unclear. We report that nucleoside
diphosphate kinaseA (NDPK-A) interacts with bothAMPKand
CFTR in overlay blots of airway epithelial cell lysates. Binding
studies in Xenopus oocytes and transfected HEK-293 cells
revealed that a CFTR peptide fragment that binds AMPK
(CFTR-1420-57) disrupted theAMPK-CFTR interaction. Intro-
duction of CFTR-1420-57 into human bronchial Calu-3 cells
enhanced forskolin-stimulated whole cell conductance in patch
clamp measurements. Similarly, injection of CFTR-1420-57
into Xenopus oocytes blocked the inhibition of cAMP-stimu-
lated CFTR conductance by AMPK in two-electrode voltage
clamp studies. AMPK also inhibited CFTR conductance with
co-expression of WT NDPK-A in two-electrode voltage clamp
studies, but co-expression of a catalytically inactive H118F
mutant or various Ser-120 NDPK-A mutants prevented this
inhibition. In vitro phosphorylation of WT NDPK-A was
enhanced by purified active AMPK, but phosphorylation was
prevented in H118F and phosphomimic Ser-120 NDPK-A
mutants. AMPK does not appear to phosphorylate NDPK-A
directly but rather promotes an NDPK-A autophosphorylation
event that involves His-118 and Ser-120. Taken together, these
results suggest that NDPK-A exists in a functional cellular com-
plex with AMPK and CFTR in airway epithelia, and NDPK-A
catalytic function is required for the AMPK-dependent regula-
tion of CFTR.
The CFTR4 Cl channel is localized to the apical membrane
of many epithelial tissues including the airway, where the most
serious clinical manifestations of cystic fibrosis (CF) occur (1).
CF-associated CFTR mutations cause abnormalities in epithe-
lial solute transport and fluid secretion with excessive airway
surface liquid reabsorption and inflammation, poor mucocili-
ary clearance, and subsequent life-threatening infections and
eventual destruction of lung tissue (2). Excessive CFTR activa-
tion in the gut underlies the secretory diarrhea in patients with
cholera (3). CFTR activity also plays an important role in the
pathogenesis of autosomal dominant polycystic kidney disease
(4). CFTR is thus directly involved in the pathophysiology of
diseases that cause excess morbidity and mortality in millions
of individualsworldwide each year (5). Amore thoroughunder-
standing ofCFTR regulation could yield important clinical ben-
efits, including therapies to boost or inhibit inappropriate levels
of CFTR activity.
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CFTR is an ATP-binding cassette family transport protein
with five major cytoplasmic domains, including two nucleo-
tide-binding domains, a regulatory R domain containing
numerous phosphorylation sites, and NH2- and COOH-termi-
nal cytoplasmic tails that interact with various proteins and
help regulate the gating and trafficking of the channel (6–8).
CFTR activation requires PKA-dependent phosphorylation of
the R-domain and ATP binding/hydrolysis at the nucleotide-
binding domains (9, 10). Of note, CFTR Cl channel activity is
down-regulated in epithelia in response tometabolic stress, but
the specific mechanisms involved are unclear (11, 12). An
important link that we have established between metabolic
state and ion transport activity is the metabolic sensor AMPK.
AMPK is a highly conserved, ubiquitously distributed Ser/
Thr kinase that exists as a heterotrimer with a catalytic  sub-
unit and regulatory and  subunits. Each subunit hasmultiple
isoforms with differing tissue distributions (13). AMPK
becomes activated in response to metabolic and other cellular
stresses and has been shown to phosphorylate a variety of target
proteins with pleiotropic effects, including modulation of cel-
lularmetabolic pathways, inflammation, cell growth and prolif-
eration, protein synthesis, and gene transcription (14).
AMPK- binds to the COOH-terminal tail of CFTR at residues
1420–1457, phosphorylates CFTR at residue Ser-768 in the R
domain, and inhibits PKA-stimulated gating of CFTR by
decreasing its open probability (Po) in cells (15–18). AMPKmay
thus limit CFTR activity in the absence of agonist stimulation.
The regulation of CFTR, an ATP-gated channel, by AMPK is
consistent with the known homeostatic role of AMPK inmain-
taining energy stores by inhibiting energy-consuming pro-
cesses and activating energy-generating processes in the cell
under conditions of metabolic stress. However, further molec-
ular details of this regulation, including the importance of
AMPK binding to CFTR and the potential involvement of addi-
tional proteins, are unknown.
Early studies performed in Xenopus oocytes suggested that
both the COOH-terminal half of the AMPK-1 catalytic sub-
unit, the region of AMPK that interacts with CFTR, and an
active kinase domain within AMPK-1 were required for
AMPK-dependent regulation of CFTR (15). However, the role
of AMPK binding to CFTR has not been explicitly tested in
cells. Additionally, the potential role of other accessory proteins
in the AMPK-dependent regulation of CFTR is unclear. Along
these lines, the nucleoside diphosphate kinase A (NDPK-A) has
been recently reported to interact and co-localize with AMPK
in respiratory tract epithelium, and there may be an important
functional inter-regulation between these two kinases (19).
Like AMPK, NDPK (also known as Nm23 and NME) is a
multifunctional, ubiquitously distributed hexameric histidine
kinase with multiple isoforms (including NDPK-A, B, C, and D
in humans; group I NDPK isoforms) (20). NDPKs catalyze the
transfer of phosphates from nucleoside triphosphates to nucle-
oside diphosphates and are involved in regulating a variety of
fundamental cellular processes, including growth and develop-
ment, G-protein signaling, metastasis, transcriptional regula-
tion, and DNA repair (20). NDPK catalytic function requires
autophosphorylation at the catalytic His-118 residue. The
nearby Ser-120 residue may also be a target for phosphoryla-
tion, which appears to play an important role in determining
NDPK function, because Ser-120 mutations affect motility and
the metastatic potential of cancer cells (19, 21, 22).
The studies conducted herein were performed to better
define the mechanisms of CFTR inhibition by AMPK. The role
of AMPK binding to CFTR was tested by introduction of a
blocking peptide corresponding to the tract in CFTR that binds
AMPK (CFTR-1420-57) into cells prior to biochemical and
electrophysiological studies. The role of NDPK-A in the regu-
lation of CFTR by AMPKwas tested through expression ofWT
and mutant NDPK-A in cells for electrophysiological studies.
Finally, theAMPK-dependent regulation ofNDPK-Aphospho-
rylation was further clarified.
EXPERIMENTAL PROCEDURES
Chemicals and Reagents—All chemicals and reagents were
obtained from Sigma unless otherwise stated.
Overlay Assays—Human bronchial epithelial (16HBE14o)
cells were cultured in medium 199 containing FBS as described
(23) until confluent. Proteins separated by SDS-PAGE were
transferred to a PVDFmembrane (Millipore) by semi-dry elec-
trophoretic transfer, and prestained markers were used to con-
firm transfer. The blots were probedwith primary antibodies to
NDPK-A (1:1000), rabbit polyclonal antibody raised to
nm23-H1 (Santa Cruz); or AMPK- (1:5000), rabbit polyclonal
antibody, gifts of D. Carling (MRCHammersmith London) and
D. G. Hardie (Dundee); or CFTR (1:1000), monoclonal anti-
body, R & D Systems (Minneapolis); or CFTR (1:1000), mono-
clonal antibody, transgene MATG103 (Strasbourg) and HRP-
conjugated anti-rabbit secondary antibody (1:2000) followed by
SuperSignal chemiluminescence detection (Pierce). NDPKwas
partially purified from a membrane fraction obtained from
ovine tracheal epithelium using a chelating Sepharose fast flow
column (20 ml) charged with ferric chloride. The membrane
fraction solubilized with 0.25% (v/v) Triton X-100 in buffer A
(0.1 M acetic acid/NaOH, pH 5.0, 0.5 M NaCl, 0.4 mM 4-(2-
aminoethyl)-benzol-sulfonylfluoride) was centrifuged at
100,000  g for 30 min at 4 °C. The supernatant fraction was
incubated at 4 °C for 1 min with ATP (50 nM) and then applied
to a chelating Sepharose fast flow column pre-equilibratedwith
buffer A. The column was then washed with buffer A, and
bound phosphoproteins were selectively eluted with 20 mM
sodium biphosphate in buffer A.
Membrane proteins (100–500 g) were resuspended in 1 ml
of immunoprecipitation (IP) buffer (10 mM Tris-HCl, pH 7.4,
containing 2 mM EDTA, 1 mM NaF, 1 mM DTT, 1% (w/v)
sodiumdeoxycholate, 1% v/vNonidet P-40, 0.3M aprotonin, 0.2
M PMSF). The mixture was then precleared with protein
G-Sepharose beads (30 min at 4 °C) and centrifuged at 4 °C at
350  g for 5 min, and the supernatant was incubated with
primary antibody to CFTR (1 g) for 1 h at 4 °C. New beads
were added, and the mixture was incubated overnight at 4 °C.
The mixture was then centrifuged at 350  g for 5 min. The
pelleted beads were washed five times in 1 ml of IP buffer con-
taining 1 MNaCl. The pelleted beads were thenwashed twice in
10 mM MOPS buffer, pH 7.9, containing 0.05% (v/v) Triton
X-100. For the overlay assays, proteins from ovine tracheal epi-
thelial membranes solubilized in 10 mM MOPS buffer, pH 7.9
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containing Chaps detergent (0.1% w/v) were then separated by
SDS-PAGE and blotted onto PVDFmembranes. NDPK-A (100
g protein) in 1TBS containing 5% (w/v) nonfat drymilk was
then overlaid onto the PVDF and incubated at room tempera-
ture for 1 h. Following washes with 1 TBS with 0.1% (v/v)
Tween 20 (four times for 15 min each), the blots were probed
with antibodies to NDPK-A (1:1000) and AMPK (1:5000).
Co-immunoprecipitation Studies—Co-IP experiments were
performed on lysates from Xenopus oocytes injected with
cRNAs to express human CFTR and HA-tagged rat AMPK-1
(5 ng/oocyte of each cRNA) 2 days prior to experimentation. A
peptide corresponding to residues 1420–1457 ofCFTR (CFTR-
1420-57) was synthesized by the University of Pittsburgh
Genomics and Proteomics Core Laboratories. This peptide (or
vehicle) wasmicroinjected into the oocytes 2–4 h prior to lysis.
CFTR was immunoprecipitated (IP’d) from lysates (50
oocytes/condition) using the M24-1 anti-CFTR mouse mono-
clonal antibody (2.5 g/IP; R & D Systems). Following SDS-
PAGE and transfer to a nitrocellulosemembrane, immunoblot-
ting was performed using HA.11 (Covance; 1:500) anti-HA and
M3A7 (Millipore; 1:700) anti-CFTR mouse monoclonal anti-
bodies. Whole cell lysate samples (5–10% of input) were run
alongside co-IP lanes, and bandswere quantitated by densitom-
etry to determine the percentage of IP’d and co-IP’d proteins
for various conditions, with corrections for differences in exog-
enous protein expression levels, as described previously (24).
Paired t tests were performed to determine the significance of
differences between blocking peptide-treated samples and
controls.
GST Pulldown Assays in HEK-293 Cells—HEK-293 cells
were co-transfected 1 day after plating using Lipofectamine
2000 (Invitrogen) with plasmids to express CFTR and either
NH2-terminal GST-tagged AMPK-1 or GST alone 2 days
prior to lysis for in vivo GST pulldown assays, based on previ-
ously describedmethods (15). On the day between transfection
and lysis, 100MCFTR-1420-57 peptide (or vehicle) was trans-
duced into cells using the BioPORTER reagent (Genlantis) as
per the manufacturer’s recommendations. After washes in ice-
cold PBS, the cells were lysed with ice-cold lysis buffer (PBS
containing 1% Triton X-100, 2 mM EDTA, and complete prote-
ase inhibitor mixture (Roche Applied Science)), and total pro-
tein concentration was estimated using the Bradford assay.
Lysate samples (1mgof total cellular protein lysate/condition
in equal volumes) were then incubated with glutathione-Sep-
harose beads on a rotator overnight at 4 °C to bind GST fusion
proteins and any interacting proteins. After washing the beads
in lysis buffer, elution at 65 °C for 15 min in sample buffer,
SDS-PAGE, and transfer to nitrocellulose membranes, immu-
noblotting was performed for either CFTR or GST usingM3A7
orGST-HRP antibodies, respectively.Whole cell lysate samples
(5% of input) were run alongside GST pulldown samples, and
the bands were quantitated by densitometry to determine rela-
tive binding of AMPK to CFTR, as described above.
Whole Cell Patch Clamp Studies—Calu-3 cells were main-
tained in 1:1DMEM/F-12medium, 10%FBS, and 1%penicillin/
streptomycin, and measurements of CFTR whole cell conduct-
ance were performed as described (16). Two days prior to patch
clamp experiments, the cellswere plated onto 25-mmglass cov-
erslips in 35-mm plastic dishes at a concentration of 8–10 
105 cells/dish. CFTR-1420-57 peptide  GFP (versus GFP
alone) were transduced into cells using the BioPORTER rea-
gent 1 day prior to patch clamp experiments. The cells were
identified for patching by their green fluorescence. Whole cell
patch clamp recordings were performed with 1 M forskolin in
the bath solution. The bath and pipette solutions used have
been described previously (25). Current-time and current-volt-
age (I-V) plots were generated by stepping from a holding
potential of20 mV to100 through100 mV in steps of 20
mV. Comparison of slope conductance values between the two
groups was performed at 40 mV, and unpaired t tests were
used to test the significance of differences between conditions.
Two-electrode Voltage Clamp Studies—Xenopus oocytes
were prepared for two-electrode voltage clamp (TEV)measure-
ments as previously described (15). Briefly, harvested oocytes
were injected with cRNAs generated using the mMessage
mMachine kit (Ambion) to express wild-type human CFTR
(1–2 ng) and NH2-terminal V5 epitope-tagged wild-type or
mutant NDPK-A cloned into the dual mammalian and oocyte
expression vector pMO (5 ng), and the oocytes were used 2–3
days post-injection for experimentation. Either 32 nl of 40 mM
potassium gluconate (control) or potassium 5-aminoimida-
zole-4-carboxamide ribonucleoside monophosphate (ZMP), a
direct cellular AMPK activator (26), was microinjected into
oocytes, and the oocytes were used within 6 h for measure-
ments (17). Once a stable base line was achieved, 1M forskolin
and 0.1 mM 3-isobutyl-1-methylxanthine (IBMX) were bath
applied via perfusionmanifold to stimulateCFTR conductance.
Evoked current wasmeasured using voltage ramps from20 to
60 mV (15). The degree of AMPK-dependent inhibition of
stimulated CFTR conductance was determined in at least 20
oocytes/condition derived fromat least three separate frogs. An
analysis of variance (ANOVA) factorialmodelwas used to com-
pare TEV data obtained from different batches of oocytes, as
described (15). In another set of TEV experiments, CFTR-
1420-57 peptide was microinjected into oocytes (final concen-
tration, 20M) to disruptAMPK-CFTR interaction. TEVmeas-
urements of peptide-injected oocytes were compared with
vehicle-injected oocytes; both groups were co-injected with
ZMP to activate AMPK.
In Vitro Phosphorylation Studies—In vitro phosphorylation
studies were performed as described (24). HEK-293 cells were
transfected with either wild-type NDPK-A or NDPK-A
mutants (H118F, S120A, S120D, S120E, S122A, and S122D)
and then lysed 1–2 days later for NDPK-A IP using 1.2 g of
anti-V5 antibody (Invitrogen). Highly purified, recombinant
active (1-T172D, 1, 1) or kinase-deficient (1-D157A, 1,
1) rat AMPKholoenzyme (27) or no-kinase control buffer was
added to examine direct, AMPK-mediated phosphorylation of
IP’d NDPK-A in vitro in the presence of [-32P]ATP. In some
studies, AMPK-phosphorylated samples were subjected to an
established acid treatment protocol to distinguish acid-labile
(i.e., His) phosphorylated residues from acid-stable Ser/Thr
linkages, as previously described (28). Briefly, IP’d NDPK-A
samples on protein A/G beads that had already been phosphor-
ylated in the presence of [-32P]ATP were then subjected to
acid (or control) washes ( addition of 10 l of 1 N HCl to the
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wash buffer to adjust the pH to 1.0) for 30 min prior to elution
in Laemmli sample buffer. SDS-PAGE, transfer, immunoblot-
ting, and phosphoscreen imaging of the same nitrocellulose
membrane were then performed. For all conditions, the ratio of
the phosphorylation signal to the immunoblot signal of the
NDPK-A band on the membrane was compared to derive rela-
tive phosphorylation levels, as described (24).
RESULTS
We previously found that AMPK activation, either pharma-
cologically or through overexpression of an activating AMPK
mutant subunit, inhibited PKA-mediated CFTR activation in
Xenopus oocytes and human bronchial serous (Calu-3) and
colonic (T84) epithelial cells (15, 16, 29). More recently, others
have reported similar data (18). Specifically, we have shown that
this AMPK-dependent inhibition of CFTR activity in Calu-3
cells occurs via an inhibition of CFTR Po in cell-attached patch
clamp studies without affecting CFTR surface expression (N),
as measured by surface biotinylation assays (16). Taken
together, it appears that AMPK acts as a brake on CFTR activ-
ity. In current Calu-3 cell studies, however, we have found that
the observed Po (0.4–0.5) in excised inside-out patch clamp
recordings with active PKA catalytic subunit and ATP in the
bath (30) was unaffected by addition of purified active AMPK
holoenzyme to the bath solution (see supplemental Fig. S1).
One interpretation of this unexpected finding is that other cel-
lular co-factors, which potentially could be lost after excision of
the patch, may be required to confer the AMPK-dependent
inhibition of CFTR in intact Calu-3 cells. Because recent work
suggests a potential functional and physical association
between NDPK-A and AMPK (19, 31, 32), we tested the
hypothesis that NDPK-A is an important co-factor in the inhi-
bition of CFTR by AMPK.
NDPK-AAssociationwith AMPKandCFTR—Overlay (or far
Western) assays were performed to identify potential binding
partners for NDPK-A in airway epithelial membranes and
examine potential interactions between NDPK-A, AMPK, and
CFTR. Our results show that NDPK-A binding to a 63-kDa
protein was detected when purified NDPK-A was overlaid on
Western blots containing solubilized membrane proteins from
ovine tracheal epithelium (Fig. 1A, lane ii). NDPK-A binding to
a 63-kDa protein was also observed when theWestern blot was
overlaid with unpurified or crude protein solution extracted
from ovine tracheal epithelial membranes using EDTA (5 mM)
(data not shown). Further analysis showed that the 63-kDa pro-
tein not only bound NDPK-A but was also immune-reactive
with antibody specific to AMPK- (Fig. 1A, lane iii, aliquot of
first lane proteins).
To further analyze the interaction, CFTR IP’d from human
bronchial epithelial (16HBE14o) cell membrane preparations
was electrophoresed and transferred to membranes, which
were then overlaid with purified NDPK-A and subsequently
immunoblottedwith antibody toNDPK-A (Fig. 1B). In addition
to showing immunoreactivity at 20 kDa (NDPK-A), addi-
tional NDPK-A antibody immunoreactivity was detectable at
63 and 175 kDa (Fig. 1B, lane ii). These data suggest that both
NDPK-A and AMPK- co-precipitated with CFTR and that
purified NDPK-A protein can interact with denatured AMPK
and CFTR in membrane blots.
Interference of CFTR-AMPK Binding by CFTR-1420-57
Peptide—Previous studies led us to propose that the interaction
ofAMPKwithCFTRmay help targetAMPKand other proteins
to CFTR in epithelial cells (15). These interactionsmay form an
efficient CFTR regulatory complex at the apical membrane. To
test whether the AMPK-1 binding tract in the CFTR COOH-
terminal tail (CFTR residues 1420–1457) could displace the
binding of AMPK to CFTR in cells, we injected Xenopus laevis
oocytes with cRNAs to co-express CFTR and HA-tagged
AMPK-1. Two days later we microinjected into the oocytes a
purified peptide corresponding to this tract (CFTR-1420-57) or
vehicle and then lysed the oocytes 4 h later for co-IP assays.
Compared with control-injected oocytes, the amount of
AMPK-1 that co-IP’d with CFTR IP’d from oocytes injected
with the CFTR-1420-57 peptide was substantially reduced (by
75  20%; Fig. 2, A, lower blot, right lanes, and B). To confirm
this result by independentmeans,HEK-293 cells were co-trans-
fected to express CFTR and either GST-tagged AMPK-1 or
GST alone. CFTR-1420-57 peptide (or vehicle) was then intro-
duced into cells by protein transduction 1 day prior to lysis,
followed by affinity purification on glutathione-Sepharose
beads (Fig. 2C, lanes 5–8). Apparent binding of CFTR to the
GST-tagged AMPK-1 was substantially reduced by the addi-
tion of the CFTR-1420-57 peptide (Fig. 2C, upper blot, lanes 6
and 8). There was no detectable binding of CFTR toGST alone.
Densitometric quantitation from three replicate experiments
confirmed that the relative CFTR binding to GST-AMPK-1
was reduced by 41 6% in the presence of the blocking peptide
(Fig. 2D). Taken together, these results indicate that the CFTR-
1420-57 peptide effectively disrupts the binding of AMPK to
CFTR when introduced into cells.
FIGURE1.NDPK-AassociationwithAMPK-andCFTR inoverlayassays. A,
immunoblots of ovine tracheal epitheliummembrane proteins (100g) per-
formed in the presence or absence of an overlay solution of purified ovine
tracheal epithelium NDPK-A (indicated by labels) and probed with either
NDPK-A (lanes i and ii) or AMPK- (lane iii) antibody. NDPK-A immunoreactiv-
ity was detected at 20 kDa and additionally at 63 kDa in overlaid blot.
AMPK- immunoreactivity was detected at 63 kDa. B, immunoblots (IB) of
immunoprecipitated CFTR from membrane fractions of polarized
16HBE14o cell lysates performed in the presence or absence of purified
NDPK overlay and probed with NDPK-A antibody. NDPK-A immunoreactivity
appears at 20 kDa (lanes i and ii) and additionally at 63 and175 kDa in overlaid
blot (lane ii), consistent with its binding to AMPK and CFTR present in the
membrane, respectively. The results shown are representative of three repli-
cate experiments.
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Transduction of CFTR-1420-57 Peptide Enhances Forskolin-
stimulated CFTR Whole Cell Conductance in Calu-3 Cells—
We previously reported that AMPK inhibits PKA-stimulated
CFTR activity in Calu-3 cells via effects on CFTR Po (16). To
investigate whether the disruption of endogenous AMPK-1
binding to CFTR modulates CFTR whole cell currents in
Calu-3 cells, we performed whole cell patch clamp studies of
forskolin-stimulated CFTR conductance in Calu-3 cells with or
without introduction of theCFTR-1420-57 peptide. Represent-
ative I-V plots are shown (Fig. 3A) in the absence or presence of
the CFTR-1420-57 peptide (upper and lower panels, respec-
tively). Cells expressing the CFTR-1420-57 blocking peptide
had significantly enhancedwhole cell conductances in the pres-
ence of PKA stimulation by60% (Fig. 3B).
AMPK Regulation of CFTR with Co-expression of Wild-type
versusH118FMutantNDPK-A inOocytes—VariousNDPK iso-
forms are ubiquitously expressed in mammalian species and in
Xenopus laevis frogs (33). We have previously shown through
TEVmeasurements that microinjection of the AMPK activator
ZMP into CFTR-expressing Xenopus oocytes inhibits cAMP-
activated CFTR conductance (17). This AMPK-dependent
inhibition of peak CFTR conductance following forskolin/
IBMX stimulation was preserved in Xenopus oocytes co-ex-
pressing CFTR and WT NDPK-A (Fig. 4, A and B). Additional
TEV measurements were performed in Xenopus oocytes
expressing NDPK-A with a Phe mutation at the site where His
phosphorylation is required for NDPK-A phosphotransfer,
which is a prerequisite for its catalytic function as a phospho-
transferase (NDPK-A-H118F) (19). The AMPK-dependent
inhibition of cAMP-stimulated CFTR conductance was abro-
gated in oocytes expressing the catalytically inactive NDPK-A-
H118Fmutant (Fig. 4,C andD). Together, these results suggest
that expression of this mutant has a dominant-negative effect
on endogenousNDPK activity in the oocytes and that NDPK-A
phosphotransferase function is required for the AMPK-depen-
dent inhibition of CFTR.
Disruption of CFTR Regulation by AMPK with the CFTR-
1420-57 Peptide—To testwhetherAMPKbinding toCFTR and
NDPK-A catalytic function are both necessary components of
the AMPK-dependent regulation of CFTR within the same
experiment, TEV studies were performed on oocytes co-ex-
pressing CFTR and either WT or the catalytically inactive
H118F mutant form of NDPK-A. All oocytes were then micro-
injected with the AMPK activator ZMP, with or without co-in-
jection of the CFTR-1420-57 peptide 2–4 h prior to TEVmeas-
urements (Fig. 5). In oocytes expressingWTNDPK-A, addition
of the CFTR-1420-57 blocking peptide significantly increased
CFTR conductance relative to controls by60% (Fig. 5, A and
B). In contrast, oocytes expressing NDPK-A-H118F showed no
significant increase in conductance with addition of the block-
ing peptide in both raw trace and normalized data (Fig. 5,C and
FIGURE 2.CFTR-1420-57 blocking peptide displaces binding of AMPK-1
to CFTR in oocytes and HEK-293 cells. A, Xenopus oocytes expressing both
CFTR and HA-tagged AMPK-1 cRNA (injected 2 days prior) were injected
with either CFTR-1420-57peptideor vehicle (nopeptide) 4hprior to lysis. The
lysates were used for IP (right) of CFTR using M24-1 antibody ( Ab lanes) or
no antibody as an IP control (No Ab lanes), followed by immunoblotting for
CFTR (upper panel) or co-IP’d HA-AMPK-1 (lower panel). The blots of 5% of
whole cell lysates are also shown (left lanes). B, by densitometric analysis, the
CFTR-1420-57 peptide reduced the amount of AMPK-1 co-IP’d with CFTR
(relative binding) by 75 20%. #, p 0.06, paired t test, n 3 experiments. C,
HEK-293 cells were co-transfected with plasmids to express CFTR and either
NH2-terminal GST-tagged AMPK-1 or GST alone 2 days prior to lysis. 100M
CFTR-1420-57 peptide (or vehicle) was transduced into cells using the Bio-
PORTER reagent 1 day before lysis as described under “Experimental Proce-
dures.” After GST affinity purification of the cell lysates, the proteins were
eluted in sample buffer and subjected to SDS-PAGE and immunoblotting for
either CFTR (upper) or GST (lower). The amount of CFTR pulled down was
substantially reduced following transduction of the blocking CFTR-1420-57
peptide (lane 6, top) relative to vehicle (lane 8, top). D, summary of relative
binding (relative amount of CFTR pulled down by GST-AMPK-1) in the pres-
ence of the CFTR-1420-57 peptide versus vehicle. By densitometric analysis,
the blocking peptide reduced the relative binding of CFTR to AMPK-1 by
416%. *,p0.02, paired t test,n3 replicate experiments.Con, control; IB,
immunoblot.
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D). In summary, these data indicate that under conditionswhen
AMPK is activated (ZMP-injected oocytes), blockade of AMPK
binding to CFTR by the CFTR-1420-57 peptide prevented
CFTR inhibition by AMPK, which reinforces the importance of
AMPK binding to CFTR for this inhibitory regulation. More-
over, the CFTR-1420-57 peptide failed to further enhance peak
CFTR conductance when the catalytically inactive form of
NDPK-A (H118F) was expressed, a condition that also blocked
the AMPK-dependent inhibition of CFTR (Fig. 4). Taken
together, the lack of significant further enhancement of CFTR
conductance by the CFTR-1420-57 peptide in this NDPK dys-
functional setting (where CFTR inhibition by AMPK is already
prevented) suggests that theCFTR-1420-57 peptide is acting, as
expected, by preventing the AMPK-dependent regulation of
CFTR rather than via a distinct, AMPK-independent
mechanism.
AMPK Enhances NDPK-A Autophosphorylation in Vitro—
Previous studies (15, 19) and our current data (Fig. 1) suggest
that CFTR, NDPK-A, and AMPK-1 can exist together in a
tripartite signaling complex in airway epithelial cells. A poten-
tial role for AMPK in the phosphorylation and function of
NDPK-A has not been well established. NDPK-A harboring an
H118F point mutation is catalytically inactive in cells (34), and
AMPK enhances NDPK-A phosphorylation (19, 35), but the
specific residue(s) involved are unclear. A recent study suggests
that Ser-120 is a target for AMPK-dependent phosphorylation,
but direct AMPK phosphorylation at that residue was not dem-
onstrated (35). To examine direct AMPK-mediated phosphor-
ylation of NDPK-A in vitro and test which residues may be
involved, we performed [-32P]ATP labeling of immunopre-
cipitated NDPK-A in the presence and absence of purified
active AMPK holoenzyme (Fig. 6). In the absence of AMPK,
NDPK-A phosphorylation was apparent in the WT, S120A,
S122A, and S122D mutant constructs, but minimal phosphate
labeling occurred in the H118F, S120D, and S120E mutants
(Fig. 6B). The addition of AMPK enhanced phosphorylation of
the WT and S120A and S122 mutant constructs, but not the
H118F, S120D, or S120E mutants, as summarized in Fig. 6B.
The simplest interpretation of these data is thatAMPKdoes not
directly phosphorylate NDPK-A at Ser-120 or Ser-122 (or at
any other site) but rather enhances NDPK-A autophosphoryl-
ation at His-118.Moreover, although this autophosphorylation
event is unaffected by a nearby S120A substitution, it is strongly
inhibited by a negatively charged residue at position 120, which
maymimic phosphorylation at that site or retardHis-118 phos-
phorylation. Ser-120 has been previously suggested to be phos-
phorylated (e.g., by casein kinase 2 (34)) and plays an important
regulatory role in NDPK-A function (21, 36). Together, these
results are consistent with a recently described “trans-model”
wherein the His-118 residue of NDPK-A is transiently auto-
phosphorylated by intermolecular phosphate transfer between
adjacent NDPK hexamers, an event that is required for
NDPK-A catalytic function, but then the high energy phos-
phate group on His-118 subsequently migrates to the nearby
(lower energy) Ser-120 site (22).
To test whether AMPK catalytic activity is required for the
enhancement of NDPK-A autophosphorylation, we compared
in vitro phosphate labeling of NDPK-A in the presence of cat-
alytically active AMPK (AMPK-1-T172D, 1, 1), catalyti-
cally inactive AMPK (AMPK-1-D157A, 1, 1) or no AMPK
(Fig. 6C). Only active AMPK enhanced the autophosphoryla-
FIGURE 3. CFTR-1420-57 blocking peptide transduced into Calu-3 cells
enhances CFTR whole cell conductance in the presence of forskolin. A,
representative current-time sweeps (gray) and current-voltage (I-V) plots
(black) are shown from whole cell patch clamp recordings performed in the
absence (panel i) or presence (panel ii) of CFTR-1420–57 blocking peptide. B,
summary of mean ( S.E.) slope conductances following mock transduction
or transduction with blocking peptide 1 day prior to measurements. *, p 
0.02, unpaired t test, n 4–5 patches/condition.
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tion of NDPK-A, suggesting that AMPK catalytic function is
required for this effect. Inactive AMPK failed to enhance
NDPK-A autophosphorylation relative to no kinase control.
Finally, to confirm that this phosphorylation event occurs at
an acid-labile (i.e., His) residue rather than an acid-stable (e.g.,
Ser or Thr) residue, we used an established protocol to compare
the phosphate signal of [32P]phosphate-labeled NDPK-A with
or without subsequent acid treatment (28, 37). The prior phos-
phorylation signal of eitherWTor S120AmutantNDPK-Awas
largely abolished (by90%) by a 30-min acid (pH1.0) exposure,
consistent with predominantNDPK-A phosphorylation occur-
ring at the His-118 site (Fig. 6D).
CFTR Inhibition by AMPK Is Blocked by Co-expression of
NDPK-A Ser-120 Mutants—The NDPK-A catalytic residue
His-118 is of clear functional importance in the inhibition of
CFTR by AMPK (Figs. 4 and 5). In addition, it appears that
AMPK does not directly phosphorylate NDPK-A in vitro but
rather enhances NDPK-A autophosphorylation at His-118. A
negatively charged residue at Ser-120 inhibited this autophos-
phorylation event (Fig. 6). The Ser-120 site has been previously
identified as a putative site of phosphorylation by another reg-
ulator of CFTR, casein kinase 2 (38), and plays an important
role in NDPK-A function (21, 36). More recently, it has been
shown that both theHis-118 and Ser-120 residues contribute to
autophosphorylation and NTP-synthesizing processes of
NDPK-A (22). Hence, we tested the effects of Ser-120 muta-
tions onCFTRwhole cell conductance inXenopus oocytes (Fig.
7). Under conditions inwhichCFTR andNDPK-Awild type are
expressed, ZMP injection to activate AMPK significantly
reduced whole cell CFTR conductance (stimulated by forsko-
lin/IBMX). However, this modulation was lost when mutated
NDPK-Awas expressed (S120A and S120D). No significant dif-
ferences in starting conductances were observed prior to fors-
kolin/IBMX stimulation. We conclude that both the His-118
and Ser-120 residues are involved in the AMPK-dependent
modulation of CFTR. Specifically, mutations of either His-118
or Ser-120 disrupt the AMPK-dependent inhibition of CFTR,
suggesting that autophosphorylation of NDPK-A at His-118,
and potentially the ability to transfer the phosphate group (for
example, to Ser-120 or to some other protein), may play an
important role in this regulation.
DISCUSSION
We and others have shown that the ubiquitous metabolic
sensor AMPK regulates CFTR and other transport proteins,
which may couple their activities to cellular metabolic status
(39, 40). Our previous studies demonstrated that AMPK binds
to the COOH-terminal tail of CFTR, phosphorylates CFTR,
FIGURE 4. AMPK fails to inhibit CFTR in oocytes expressing catalytically inactive NDPK-A-H118F mutant. TEV recordings were performed 2 days after
cRNA injection of CFTR and either wild-type NDPK-A (NDPK-AWT) or the catalytically inactive NDPK-A-H118Fmutant into Xenopus oocytes. The oocytes were
injected 2–4 h prior to recording with either potassium gluconate (Control) or the AMPK activator K-ZMP (ZMP). A and C, the mean ( S.E.) whole cell
conductances are shownover time following addition of the cAMP agonists forskolin (1M) and IBMX (0.1mM) at time 0 to activate CFTR in oocytes expressing
either NDPK-AWT (A) or the NDPK-A-H118Fmutant (C). B, ZMP injection inhibited the peak CFTR conductance in oocytes co-expressing CFTR and NDPK-AWT
relative to control-injected oocytes. *, p 0.001, ANOVA; data normalized to peak control-injected current. D, ZMP failed to inhibit CFTR conductance with
co-expression of the catalytically inactive NDPK-A-H118F mutant (p  0.10, ANOVA). Starting conductances were lower than peak conductances for all
conditions. #, p 0.001, ANOVA; n 15–30 oocytes/condition from four to seven separate frogs for all conditions shown.
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and inhibits PKA-stimulated CFTR gating (Po) in epithelial
cells (15–18).
Here we have further explored the molecular and cellular
mechanisms underpinning this regulationwith respect to bind-
ing of AMPK to CFTR within a multiprotein regulatory com-
plex and demonstrate the importance of NDPK-A function in
this regulation. As previously suggested (19), NDPK-A appears
to exist along with AMPK and CFTR in an apical membrane
multiprotein complex in airway epithelial cells. Purified
NDPK-Abound to gel-denaturedAMPK-1 andCFTRderived
from airway epithelial cell membrane fractions (Fig. 1), consist-
ent with a putative role for NDPK-A in the regulation of CFTR
by AMPK. Introduction of the CFTR-1420-57 blocking peptide
into cells interfered with the CFTR-AMPK-1 interaction (Fig.
2), reduced the tonic inhibition induced by AMPK on CFTR in
Calu-3 whole cell patch clamp recordings (Fig. 3), and dis-
rupted the AMPK-dependent inhibition of CFTR in oocytes
(Fig. 5). Together, these results confirm the requirement of
AMPK binding to CFTR in its capacity to inhibit the degree of
CFTR activity.
Overexpression of wild-type NDPK-A in oocytes (Fig. 4) had
no qualitative effect on the previously describedAMPK-depen-
dent inhibition of cAMP-stimulated CFTR conductance in the
absence of exogenous NDPK expression (17). This finding is
consistent with the notion that there is endogenous NDPK in
the oocytes (33), which allows AMPK to regulate CFTR there
in the absence of exogenous NDPK co-expression. Expression
of the catalytically inactive H118F NDPK-A, on the other
hand, abrogated the inhibition of CFTR by AMPK in oocytes
(Fig. 4, C and D). This finding suggests that the overexpression
of mutant NDPK-A has a dominant-negative effect on endog-
enous oocyte NDPK, presumably by getting incorporated into
endogenous NDPK hexamers and thereby interfering with
NDPK catalytic function in the oocytes. This interference pre-
sumably blocks the AMPK-dependent inhibition of CFTR, sug-
gesting that NDPK-A plays a key role in this regulation. Under
conditions ofAMPKactivation, the lack of additive response on
the enhancement of CFTR conductance in oocytes expressing
bothNDPK-A-H118F and the blocking CFTR-1420-57 peptide
(Fig. 5) is consistent with the idea that these two factors act
within the same pathway for CFTR regulation (i.e., they are
both important components of the AMPK regulatory mecha-
nism). This idea fits well with a recent report that the homo-
logue of NDPK-A found in the amoeba Dictyostelium is
required to transmit the energy conservation signal induced by
activated AMPK (32). Together, this recently published study
and our current results suggest that AMPK and NDPK lie
FIGURE 5. Importance of both AMPK binding to CFTR and NDPK-A catalytic function for the inhibition of CFTR by AMPK in oocytes. TEV experiments
wereperformed2days aftermicroinjectionofXenopusoocyteswith cRNAs to expressCFTRandeitherNDPK-AWTorNDPK-A-H118Fmutant. Theoocyteswere
microinjected with either ZMP alone or ZMP CFTR-1420-57 peptide 4 h prior to TEV recordings. Forskolin and IBMX were infused at time 0 to activate CFTR
conductance. A, summary of mean ( S.E.) changes in whole cell conductance over time are shown in oocytes expressing NDPK-A WT. B, mean ( S.E.)
conductances are shown relative to the peak conductance for the ZMP alone condition. The addition of the CFTR-1420-57 blocking peptide induced a
significant increase in peak conductance relative to control. *, p 0.002 (ANOVA). C, summary of mean ( S.E.) changes in whole cell conductance over time
is shown in oocytes expressingNDPK-A-H118F.D, normalized data for CFTR andNDPKA-H118F condition showno significant change in either peak or starting
conductances by the CFTR-1420-57 peptide. n 23–25 oocytes from five separate frogs for all conditions shown).
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within the same functional cellular pathways and that NDPK
may play an important role in transducing cellular AMPK
signals.
Our in vitro phosphorylation studies confirm that AMPK
enhances the phosphorylation ofNDPK-A, as recently reported
(19, 35). AMPK catalytic activity appears to be required for this
phosphorylation enhancement, which is also acid-labile and
almost entirely blocked in the NDPK-A-H118F mutant or with
negatively charged, acidic residue substitutions at the nearby
Ser-120 residue (Fig. 6). Of note, there was no decrement in
phosphorylation in vitro with the NDPK-A-S120A mutant rel-
ative to WT NDPK-A. Taken together, these results suggest
that AMPK does not directly phosphorylate NDPK-A at Ser-
120 (or at any other residue) but instead enhances NDPK-A
autophosphorylation predominantly at the catalytic His-118
residue.We speculate that negatively charged residue substitu-
tions at Ser-120 inhibit this NDPK-A autophosphorylation at
His-118 via local electrostatic charge effects. Additionally,
mutation of the Ser-120 site disrupts AMPK-dependent inhibi-
tion of CFTR in oocytes (Fig. 7), suggesting that phosphate
transfer from His-118 to Ser-120, as recently proposed (22),
could be a key component in the regulatory mechanism. Alter-
natively, neutral or charged substitutions at this site may inter-
fere with NDPK-A catalytic function by disrupting the local
conformation at or near the catalytic site of the kinase. Regard-
less of the mechanism, these data support the idea that
NDPK-A catalytic function is required for the AMPK-depen-
dent inhibition of CFTR.
At first glance, our resultsmay appear to be inconsistent with
a recent study reporting that the NDPK-A Ser-120 residue is a
FIGURE 6.AMPKenhancesNDPK-A autophosphorylation at His-118 in vitro. A, WT or indicatedNDPK-Amutantswere immunoprecipitated and subjected
to in vitro phosphorylation by [-32P]ATP labeling in the presence () or absence () of purified active AMPK holoenzyme AMPK-1-T172D, -1, -1. Immu-
noblotting (lower panel) and phosphoscreen imaging (upper panel) were then performed on the same nitrocellulose membrane, as described under “Experi-
mental Procedures.” B, summary of mean ( S.E.) NDPK-A phosphorylation signal normalized to expression levels and reported relative to WT NDPK-A
phosphorylation in the presence of AMPK. *, p 0.02, paired t test relative to sameNDPK-A construct in presence of AMPK; #, p 0.001 relative toWTNDPK-A
in presence of AMPK, unpaired t-tests; data pooled from three to eleven experiments for each condition. These results suggest that AMPK does not directly
phosphorylate NDPK-A at Ser-120 or Ser-122 (or any other site) but rather enhances an NDPK-A autophosphorylation event at His-118. C, in vitro phosphoryl-
ation assays were performed using active AMPK holoenzyme (AMPK-1-T172D, -1, -1), kinase-dead holoenzyme (AMPK-1-D157A, -1, -1), or no kinase,
andmean ( S.E.) phosphorylation values relative to active AMPK condition are shown. *, p 0.001, unpaired t test relative to active AMPK; n 8.D, acid (or
control) washes ( addition of 10 l of 1 N HCl to wash buffer to adjust the pH to 1.0 for 30 min) of the IP’d NDPK-A on protein A/G beads were performed
following in vitrophosphorylation to detectwhether phosphorylation hadoccurred at an acid-labile (i.e., His) residue inNDPK-A. *,p 0.05; #,p 0.05, relative
to AMPK condition of same NDPK-A species, unpaired t-tests, n 3–4 experiments for each condition.
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target for AMPK phosphorylation in vivo (35). However, direct
AMPK-mediated phosphorylation at that residue was not
tested in vitro. Rather, Onyenwoke et al. (35) showed that
NDPK-A phosphorylation was reduced in brain AMPK-1/2
double knock-out mice by two-dimensional differential in-gel
electrophoresis analyses, and they showed AMPK-dependent
modulation of Ser-120 phosphorylation in vivo by mass
spectrometry.
AMPK and NDPK regulate adjacent enzymes in fatty acid
metabolism. AMPK controls acetyl CoA carboxylase (13), a
gatekeeper of fatty acid balance, and NDPK controls the cyto-
solic enzyme ATP-citrate lyase (41), which cleaves the acetyl
CoA from citrate recently exported from the mitochondrion.
Thus, our finding that both proteins interact with an ion chan-
nel (and regulate one another) creates a new dimension to the
links between ion transport processes that consume a large pro-
portion of cellular energy and the cellular energy charge. That
both AMPK and NDPK-A function to retard CFTR function is
consistent with such a linking role and is of particular interest
given the reported relationship between in vitroCl concentra-
tion and the intensity of phosphorylation of NDPK in airway
membranes (42).
The notion that an additional accessory protein, such as
NDPK-A, is required for the regulation of CFTR by AMPK is
attractive, because the AMPK-mediated phosphorylation of
CFTR at Ser-768 in the R domain is clearly not sufficient to
account for the inhibition by AMPK of CFTR (17). Specifically,
PKA can also phosphorylate this residue, but PKA has the
opposite (stimulatory) effect on CFTR (43). There are at least
two potential mechanisms, not necessarily mutually exclusive,
to explain the necessary role of NDPK-A in the regulation of
CFTR by AMPK. The first involves a previously proposed “sub-
strate channeling” model whereby nucleotides (e.g., ATP) are
directly supplied (enzymic mouth-to-mouth coupling) to
AMPK via its close association with NDPK-A, which catalyzes
the interconversion of cellular nucleotide pools (e.g., GTP 
ADP 3 ATP  GDP) (31). This process could provide the
catalytic AMPK-1 subunit with a local supply of ATP that
could be used to phosphorylate and inhibit theCFTRCl chan-
nel even under conditions when bulk cellular pools of ATPmay
be reduced, as with metabolic depletion. A second potential
mechanism for the involvement of NDPK-A in the AMPK-de-
pendent regulation of CFTR is that NDPK-A acts downstream
of AMPK between AMPK and CFTR. In support of this model,
our current data and previous work suggest that AMPK recip-
rocally modulates NDPK-A function. NDPK-A may, in turn,
modulate signaling mediators that regulate CFTR activity. For
example,Gs proteins are known signalingmediatorsmodulated
by NDPK-B (44), and CFTR activity at the plasma membrane
has been shown to bemodulated byG-proteins (45).Moreover,
CFTR trafficking/localization is regulated by Rab-GTPases
(46), some of which are linked to NDPK function (47). Further
studies are warranted to explore the mechanism(s) by which
NDPK-A contributes to the regulation of CFTR by AMPK.
Of note, AMPK, a kinase thought to be AMP-activated, is
now known to be additionally activatable by ADP, which pre-
vents AMPKdephosphorylation (48). These recent findings are
of particular interest given that ADP is a substrate for NDPK
that could be either fed or removed from the vicinity of AMPK.
Thus, it is conceivable that NDPK-A also plays an important
role in theAMPK-dependent regulation of other transport pro-
teins and in the pleiotropic effects of AMPK on a variety of
cellular pathways and functions.
A better understanding of NDPK-A function and regulation
is of broad interest to understanding human health and disease.
Previous work has shown that phosphorylation of WT NDPK
decreases the metastatic potential of cancer cells, whereas
S120G or S120Amutants did not (21, 36). Another study impli-
cated Ser-120 as a target for casein kinase 2 phosphorylation,
which inhibits the autophosphorylation of His-118 (34). Phos-
phorylation of the His-118 residue has also been shown to be
defective in the pancreatic islets of a diabetic rat model (49).
Relative to CF therapeutics, the strategy of blocking the
CFTR-AMPK interaction in vivo (e.g., through the use of our
CFTR-1420-57 blocking peptide or a small molecule com-
pound found to disrupt the AMPK-CFTR interaction) could be
beneficial in ameliorating CF lung disease by enhancing CFTR
function. CF patients have diminished CFTR function and
increased (but mislocalized) AMPK levels (50). Therefore, in
CF patients with residual CFTR function in the airway, it may
be attractive to enhance AMPK activation by treatment with an
AMPK activator such as metformin to inhibit excessive airway
inflammation and epithelial Na channel-mediated fluid reab-
sorption (51) while selectively preventing the AMPK-depen-
dent inhibition of CFTR with such a compound.
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FIGURE7.NDPK-AS120mutantsdisrupt theAMPK-dependent inhibition
of CFTR in oocytes. TEV recordings were performed 2 days after cRNA injec-
tion of CFTR and NDPK-A WT or S120A and S120D mutants. 2–4 h prior to
recording, oocytes were injected with either potassium gluconate (Con) or
the AMPK activator K-ZMP (ZMP). Starting and peak conductances were
measured before and after the addition of forskolin (1M) and IBMX (0.1mM).
A significant decrease in peak conductance was observed following ZMP
treatment with co-expression of WT NDPK-A (*, p  0.01 relative to Con,
ANOVA), whereas this inhibition was lost with co-expression of NDPK-A-
S120A and -S120D mutants (p 0.10 between control and ZMP conditions,
ANOVA). Starting conductances for all NDPK-A species were significantly
lower than corresponding peak conductances. #, p 0.001; n 12 oocytes
for each condition from three separate frogs.
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
Excised patch-clamp recordings and analysis - Excised, inside-out patch-clamp recordings were 
performed on Calu-3 cells 1–3 days after plating onto sterile coverslips, essentially as described 
previously (1). The bath solution contained (in mM): 140 NaCl, 2 MgCl2, 0.1 CaCl2, 1 EGTA, 1 MgATP, 
1 NaAMP and 10 HEPES (pH 7.5) with 200 units/ml PKA catalytic subunit (Promega). The pipette 
solution was the same but without ATP, AMP and PKA. Forskolin (1 µM) was added to the bath solution 
to stimulate CFTR in intact cells and facilitate CFTR channel detection. Purified, highly active AMPK 
holoenzyme (2 !l) isolated from rat liver (Upstate) was added to the bath solution after at least 5 min of 
single-channel recordings were performed. All experiments were performed at room temperature and ± 
60-mV transmembrane potential. Single-channel currents were acquired using an Axon 2B patch-clamp 
amplifier (Axon Instruments) filtered at 100 Hz, and recorded using PULSE + PULSEFIT software 
(HEKA Electronics). Current records of at least 5-min duration were analyzed for each experimental 
condition by TAC software (Bruxton) for Po evaluation. The total number of channels in a patch was 
assumed to be the maximum number of open-channel current levels observed over the full duration of the 
experiment (at least 10 min). The data were fitted and modeled using IGOR PRO software 
(WaveMetrics). 
 
SUPPLEMENTAL FIGURE LEGENDS 
Figure S1 – PKA-stimulated CFTR gating in excised patches before (Control) and after addition of 
AMPK (+ AMPK) to the bath. A. Typical single-channel traces performed at a holding potential of -60 
mV. Arrow signifies closed channel state. B. Mean Po ± SEM in absence and presence of AMPK. Po was 
unchanged after AMPK addition (p > 0.10, n = 7, paired t-test). 
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